Oncotelic Therapeutics Files 8-K

TL;DR

Oncotelic Therapeutics filed an 8-K on 4/29 for an event on 4/26. Check for details.

AI Summary

Oncotelic Therapeutics, Inc. filed an 8-K on April 29, 2024, reporting an event that occurred on April 26, 2024. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. The company, formerly known as Mateon Therapeutics Inc. and Oxigene Inc., is incorporated in Delaware and headquartered in Agoura Hills, CA.

Why It Matters

This 8-K filing indicates a material event has occurred for Oncotelic Therapeutics, requiring public disclosure. Investors should review the filing for details on the nature of the event and its potential impact.

Risk Assessment

Risk Level: medium — 8-K filings often disclose significant corporate events that can impact stock price, necessitating careful review by investors.

Key Players & Entities

• Oncotelic Therapeutics, Inc. (company) — Registrant
• April 26, 2024 (date) — Date of earliest event reported
• April 29, 2024 (date) — Date of report
• Mateon Therapeutics Inc. (company) — Former company name
• Oxigene Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• Agoura Hills, CA (location) — Principal executive offices
• (650) 635-7000 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $15 million — e Term Sheet, Mosaic will pay Oncotelic $15 million in shares upon the closing of a definit
• $2.0 — which will include an annual budget of $2.0 – $2.5 million, (2) Oncotelic will loan
• $2.5 m — will include an annual budget of $2.0 – $2.5 million, (2) Oncotelic will loan Mosaic f
• $2 million — yable upon Mosaic raising financings of $2 million or more, in cash or additional shares o

Filing Documents

• form8-k.htm (8-K) — 44KB
• ex10-1.htm (EX-10.1) — 38KB
• ex99-1.htm (EX-99.1) — 19KB
• ex10-1_001.jpg (GRAPHIC) — 36KB
• ex10-1_002.jpg (GRAPHIC) — 1KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• 0001493152-24-016839.txt ( ) — 343KB
• otlc-20240426.xsd (EX-101.SCH) — 3KB
• otlc-20240426_lab.xml (EX-101.LAB) — 33KB
• otlc-20240426_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 ONCOTELIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-21990 13-3679168 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 29397 Agoura Road , Suite 107 Agoura Hills , CA 91301 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code (650) 635-7000 Not applicable. (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of class Trading Symbols Name of each exchange on which registered N/A OTLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On April 29, 2024, Oncotelic Therapeutics, Inc. (the " Company ") issued a press release announcing that the Company had entered into a binding term sheet (the " Term Sheet ") with Mosaic ImmunoEngineering, Inc. (" Mosaic "). The Term Sheet was entered into on April 26, 2024. As per the terms contained in the Term Sheet, Mosaic will pay Oncotelic $15 million in shares upon the closing of a definitive agreement for certain pre-agreed indications of CA4P. In addition, Oncotelic may earn upto $15 million in cash and $15 million in shares of Mosaic, upon achievement of certain agreed upon milestones. Additional terms of the Term Sheet include that (1) Mosiac to continue the development work necessary to achieve the mutually agreed upon milestones which will include an annual budget of $2.0 – $2.5 million, (2) Oncotelic will loan Mosaic funds to cover Mosaic's annual audit and operational costs till June 1, 2024, at terms to be decided, and repayable upon Mosaic raising financings of $2 million or more, in cash or additional shares of Mosaic (3) Oncotelic will assist Mosaic to raise at least $2 million to fund the operations of Mosaic and (4) in the event Oncotelic is unable to assist Mosiac raise the required funds as per clause 3 above, then the transaction shall move forward as a reverse acquisition/merger, with conditions typical of such a transaction. Pursuant to the Term Sheet, the parties agreed to negotiate in good faith towards the execution of the Definitive Agreements and the closing of the transactions contemplated thereby, which will be subject to customary due diligence and other conditions as described in the Term Sheet. A copy of the press release is attached hereto as Exhibit 99.1. Disclaimer. The information in Section 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibits 10.1 and 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Filed on 10.1 Binding Term Sheet dated April 26, 2024 April 29, 2024 99.1 Press Release dated April 29, 2024 April 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mosaic ImmunoEngineering Inc. Date: April 29, 2024 By: /s/ Vuong Trieu Vuong Trieu, Ph. D. President and Chief Executive Officer, Director

View Full Filing

View this 8-K filing on SEC EDGAR